^
Association details:
| Biomarker: | CD123 overexpression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | flotetuzumab (MGD006) (CD3 agonist, CD123 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
Published date:
11/06/2019
Excerpt:
Pts with CR showed higher CD123 RD compared to pts with no response (15186.5 vs 10836.8 sites/cell). FLZ anti-leukemic activity (>30% decrease in BM blasts) was associated with increased baseline immune gene signatures, including significantly higher IFNγ scores (1.8 FC, p=0.0212; AUROC=0.74), and an increased tumor inflammation signature (TIS) score (1.658 FC, p=0.00827, AUROC=0.847 compared to non-responders.
DOI:
https://doi.org/10.1182/blood-2019-122073
